Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock performance was 0.22% in last session and finished the day at $13.94. Traded volume was million shares in the last session and the average volume of the stock remained 815.19K shares. The beta of the stock remained -0.21. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider ownership is 1.20%.

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with hematologic malignancies at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Karyopharm Therapeutics Inc (NASDAQ:KPTI) dropped -1.36 percent to $26.12 Tuesday on volume of 185.40K shares. The intra-day range of the stock was $25.79 to $26.58. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has a market capitalization of $777.40million.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that the Company will be presenting at the Jefferies 2014 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Catalyst’s Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Thursday, June 5th at 2:00 pm ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s stock on June 03, 2014 reported a decrease of -2.74% to the closing price of $2.13. Its fifty two weeks range is $0.83 -$3.65. The total market capitalization recorded $143.07million. The overall volume in the last trading session was 369.50K shares. In its share capital, CPRX has 67.18million outstanding shares.

United Therapeutics Corporation paid Supernus Pharmaceuticals Inc (NASDAQ:SUPN) a $2 million milestone payment for the launch of United’s Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in the United States. On Tuesday, shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) dropped -1.15% to close the day at $8.61. Company return on investment (ROI) is -105.30% and its monthly performance is recorded as 7.62%. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) quarterly revenue growth is -16.00%.

The Medicines Company (NASDAQ:MDCO)‘s stock had its “neutral” rating restated by Zacks in a research report issued on Friday. They currently have a $29.00 price target on the stock. Zacks‘s price objective suggests a potential upside of 3.35% from the stock’s previous close. The Medicines Company (NASDAQ:MDCO) stock performance was 0.04% in last session and finished the day at $28.07. Traded volume was 600.60K shares in the last session and the average volume of the stock remained 956.77K shares. The beta of the stock remained 0.93. The Medicines Company (NASDAQ:MDCO) insider ownership is 1.00%.